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upon injection would increase cell transplant retention and survival
within the infarct, compared with the standard injection technique.”
The investigators failed to acknowledge that this theory was
presented by our group at the American Heart Association meetings
in 2001 and the American College of Cardiology meetings in 2002
and 2003. Neither do they reference our published works (both
experimental and clinical) evaluating the role of fibrin matrices as a
scaffold for cell transplantation and as an angiogenic agent. Using
transmission electron microscopy, we discovered that fibrin platform
directs the morphofunctional process of capillary formation and
accelerates neovascularization in ischemic myocardium in addition to
enhancing the viability of transplanted endothelial cells (2,3).
We documented improvement in left ventricular ejection frac-
tion, myocardial blood, and capillary density.
We avoided the possibility of higher graft rejection from using
an inbred strain and allograft transplantation, the limitation the
investigators mention, by employing autologous endothelial cells
and autologous fibrinogen for fibrin sealant preparation. Endothe-
lial cells (ECs) were cultivated from endothelium of the jugular
veins of the same sheep (3). One week before EC transplantation,
whole blood from each animal was collected, and a standard
cryoprecipitate technique was used to prepare autologous fibrino-
gen from sheep plasma. Cultured in a two-dimensional fibrin
matrix, ECs quickly formed a cobblestone monolayer that had a
density 2- to 2.5-fold higher than in controls cultivated on a
single-plane tissue culture surface (4). We also found that, cultured in
a three-dimensional fibrin matrix, ECs formed true capillaries, while
other vascular cells trapped in this matrix underwent apoptosis.
In our next investigation, we found that a fibrin-based sealant
becomes vascularized when placed between two ischemic tissues and
that aprotinin, added to fibrinogen, considerably increased the process
of neovascularization (5). Fibrin-based sealant proved capable of
delivering plasma proteins necessary to perform the functions of an
extracellular matrix, anchoring ECs to the vessel wall (6).
Finally, we demonstrated that fibrin-based sealant accelerates
angiogenesis in patients with peripheral artery disease (7).
We thank Christman et al. (1) for their interesting contribution
on this subject and applaud the renewed interest in this worthy line
of inquiry. With further preclinical and clinical investigation of the
safety and efficacy of this technique, we believe that fibrin matrix
as a scaffold for cell therapy, and the angiogenic potential of fibrin
compositions, show promise for the treatment of heart disease.
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REPLY
Our report (1) is the first study to demonstrate the beneficial effects
of intramyocardial injection of a biopolymer alone in inducing
angiogenesis and reducing infarct expansion. Furthermore, we
have demonstrated that compositions of fibrin glue injected into
ischemic myocardium prevent the negative remodeling associated
with a myocardial infarction (MI) (2). These dramatic results were
shown both for fibrin glue alone, and in material compositions of
fibrin glue combined with transplanted, healthy myoblasts. Addi-
tionally, our report demonstrated that a fibrin glue scaffold
increased the survival of contractile-type muscle cells, more spe-
cifically myoblasts, transplanted into myocardial tissue.
One hypothesis we tested was that an acellular intramyocardial
injection of a biopolymer could prevent infarct expansion and
prevent the continued worsening in left ventricular (LV) function
following an MI. Dr. Chekanov and colleagues provide corrobo-
rative data regarding the utility of biopolymers. However, the
emphasis of the experiments cited by Chekanov and colleagues had
different objectives. In their earlier citations (3), Chekanov et al.
used an autologous biologic glue containing fibrinogen epicardially
to enhance the healing process of cardiomyoplasty. The autologous
biologic glue was used “as an interlayer between the stimulated
latissimus dorsi muscle and the myocardium to improve adhesion
formation and cardiomyoplasty results.”
Another hypothesis we tested was that fibrin glue matrix, in
combination with myoblasts, enhances LV function. This test was
specifically designed around use of a contractile type of cells.
Accordingly, our work demonstrates an advancement by showing
pronounced beneficial effects of fibrin glue-assisted myoblast
transplantation into ischemic myocardium. Chekanov et al. (4) did
report results of an experimental protocol to observe the effects of
transplanting endothelial cells (ECs) in a fibrin matrix into
ischemic myocardium. However, the experimental design was
principally based upon a hypothesis of neovascularization and
consisted of the following three groups: 1) ECs and fibrin matrix,
2) saline with denatured cells, and 3) a control group. The
investigators did not include a fibrin matrix group alone or healthy
ECs alone. Therefore, they did not test whether a biopolymer
alone injected intramyocardially could produce angiogenesis or
prevent the negative remodeling associated with an MI.
Additionally, without observing the effects of a healthy EC
group without fibrin glue, the researchers could not determine the
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extent to which a fibrin matrix is beneficial in increasing cell
transplantation and survival in the setting of myocardial injections.
Still further, Chekanov and colleagues did not report any test
protocols or observations regarding intramyocardial injections of
fibrin glue in combination with contractile types of cells such as
myoblasts.
The work done by Chekanov and colleagues is very interesting
with respect to the objectives, experiences, observations, and results
of their specific studies. Also, our work (1,2) does share some basic
common features with the findings cited by Chekanov et al.
However, the advances we made provide substantially new and
different compositions of therapeutic materials, in vivo applica-
tions, and observations and results. Our work thus offers unique
advancements and implications with respect to possible future
applications to patient care. This is in particular the case with
respect to demonstrating the benefits of injecting (a) acellular
fibrin glue agents and (b) fibrin glue agents together with trans-
planted contractile-type cells (e.g., myoblasts) into ischemic myo-
cardium.
Despite the distinct differences noted, we thank Dr. Chekanov
and colleagues for sharing their experience with fibrin glue and to
the advancement of the use of polymers as potential therapeutic
agents.
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